Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16982322rdf:typepubmed:Citationlld:pubmed
pubmed-article:16982322lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:16982322lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:16982322lifeskim:mentionsumls-concept:C0026764lld:lifeskim
pubmed-article:16982322lifeskim:mentionsumls-concept:C0079459lld:lifeskim
pubmed-article:16982322lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:16982322lifeskim:mentionsumls-concept:C0005767lld:lifeskim
pubmed-article:16982322lifeskim:mentionsumls-concept:C0027950lld:lifeskim
pubmed-article:16982322lifeskim:mentionsumls-concept:C1504389lld:lifeskim
pubmed-article:16982322lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:16982322lifeskim:mentionsumls-concept:C1136535lld:lifeskim
pubmed-article:16982322lifeskim:mentionsumls-concept:C0439859lld:lifeskim
pubmed-article:16982322lifeskim:mentionsumls-concept:C1328050lld:lifeskim
pubmed-article:16982322pubmed:issue10lld:pubmed
pubmed-article:16982322pubmed:dateCreated2006-9-19lld:pubmed
pubmed-article:16982322pubmed:abstractTextPegfilgrastim has shown to decrease the duration of severe neutropenia after conventional chemotherapy, but its use after high-dose chemotherapy and autologous blood stem cell transplantation has not been established yet. Therefore we studied the efficacy and the pharmacokinetic profile of pegfilgrastim in patients with multiple myeloma undergoing high-dose chemotherapy.lld:pubmed
pubmed-article:16982322pubmed:languageenglld:pubmed
pubmed-article:16982322pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16982322pubmed:citationSubsetIMlld:pubmed
pubmed-article:16982322pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16982322pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16982322pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16982322pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16982322pubmed:statusMEDLINElld:pubmed
pubmed-article:16982322pubmed:monthOctlld:pubmed
pubmed-article:16982322pubmed:issn0301-472Xlld:pubmed
pubmed-article:16982322pubmed:authorpubmed-author:HaasRainerRlld:pubmed
pubmed-article:16982322pubmed:authorpubmed-author:SteidlUlrichUlld:pubmed
pubmed-article:16982322pubmed:authorpubmed-author:FenkRolandRlld:pubmed
pubmed-article:16982322pubmed:authorpubmed-author:KobbeGuidoGlld:pubmed
pubmed-article:16982322pubmed:authorpubmed-author:ZohrenFabianFlld:pubmed
pubmed-article:16982322pubmed:authorpubmed-author:BrunsIngmarIlld:pubmed
pubmed-article:16982322pubmed:authorpubmed-author:GraefThorsten...lld:pubmed
pubmed-article:16982322pubmed:authorpubmed-author:RufLeilaniLlld:pubmed
pubmed-article:16982322pubmed:authorpubmed-author:HieronimusNad...lld:pubmed
pubmed-article:16982322pubmed:issnTypePrintlld:pubmed
pubmed-article:16982322pubmed:volume34lld:pubmed
pubmed-article:16982322pubmed:ownerNLMlld:pubmed
pubmed-article:16982322pubmed:authorsCompleteYlld:pubmed
pubmed-article:16982322pubmed:pagination1296-302lld:pubmed
pubmed-article:16982322pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:16982322pubmed:meshHeadingpubmed-meshheading:16982322...lld:pubmed
pubmed-article:16982322pubmed:meshHeadingpubmed-meshheading:16982322...lld:pubmed
pubmed-article:16982322pubmed:meshHeadingpubmed-meshheading:16982322...lld:pubmed
pubmed-article:16982322pubmed:meshHeadingpubmed-meshheading:16982322...lld:pubmed
pubmed-article:16982322pubmed:meshHeadingpubmed-meshheading:16982322...lld:pubmed
pubmed-article:16982322pubmed:meshHeadingpubmed-meshheading:16982322...lld:pubmed
pubmed-article:16982322pubmed:meshHeadingpubmed-meshheading:16982322...lld:pubmed
pubmed-article:16982322pubmed:meshHeadingpubmed-meshheading:16982322...lld:pubmed
pubmed-article:16982322pubmed:meshHeadingpubmed-meshheading:16982322...lld:pubmed
pubmed-article:16982322pubmed:meshHeadingpubmed-meshheading:16982322...lld:pubmed
pubmed-article:16982322pubmed:meshHeadingpubmed-meshheading:16982322...lld:pubmed
pubmed-article:16982322pubmed:meshHeadingpubmed-meshheading:16982322...lld:pubmed
pubmed-article:16982322pubmed:meshHeadingpubmed-meshheading:16982322...lld:pubmed
pubmed-article:16982322pubmed:meshHeadingpubmed-meshheading:16982322...lld:pubmed
pubmed-article:16982322pubmed:meshHeadingpubmed-meshheading:16982322...lld:pubmed
pubmed-article:16982322pubmed:meshHeadingpubmed-meshheading:16982322...lld:pubmed
pubmed-article:16982322pubmed:meshHeadingpubmed-meshheading:16982322...lld:pubmed
pubmed-article:16982322pubmed:meshHeadingpubmed-meshheading:16982322...lld:pubmed
pubmed-article:16982322pubmed:year2006lld:pubmed
pubmed-article:16982322pubmed:articleTitleSustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma.lld:pubmed
pubmed-article:16982322pubmed:affiliationDepartment of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Duesseldorf, Germany.lld:pubmed
pubmed-article:16982322pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16982322pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:16982322pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed